Moreover, NVG-111 is a BiTE-targeting Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1)—a protein which is expressed at high levels on many types of cancers, including CLL and CD3—and was evaluated in a phase I trial in patients with R/R ROR1 + malignancies including patients with CLL (NCT04763083). Here, ROR1 is linked to cancer.